DexCom Short Long Term Debt Total from 2010 to 2024

DXCM Stock  USD 78.10  0.16  0.21%   
DexCom Short and Long Term Debt Total yearly trend continues to be very stable with very little volatility. Short and Long Term Debt Total is likely to grow to about 2.7 B this year. During the period from 2010 to 2024, DexCom Short and Long Term Debt Total quarterly data regression pattern had sample variance of 1088047.5 T and median of  361,000,000. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2006-06-30
Previous Quarter
2.6 B
Current Value
2.6 B
Quarterly Volatility
969.9 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0 or PTB Ratio of 24.31. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
  
Check out the analysis of DexCom Correlation against competitors.

Latest DexCom's Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of DexCom Inc over the last few years. It is DexCom's Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

DexCom Short Long Term Debt Total Regression Statistics

Arithmetic Mean911,261,733
Geometric Mean116,623,378
Coefficient Of Variation114.47
Mean Deviation913,769,049
Median361,000,000
Standard Deviation1,043,095,136
Sample Variance1088047.5T
Range2.7B
R-Value0.93
Mean Square Error149922.4T
R-Squared0.87
Slope217,811,136
Total Sum of Squares15232664.5T

DexCom Short Long Term Debt Total History

20242.7 B
20232.6 B
20222.1 B
20211.8 B
20201.8 B
20191.1 B
2018B

About DexCom Financial Statements

DexCom investors utilize fundamental indicators, such as Short Long Term Debt Total, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Short and Long Term Debt Total2.6 B2.7 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out the analysis of DexCom Correlation against competitors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.157
Earnings Share
1.66
Revenue Per Share
10.089
Quarterly Revenue Growth
0.02
Return On Assets
0.0606
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.